A numerical prognostic index for clinical use in identification of poor-risk patients with hodgkin's disease at diagnosis

Stephen J. Proctor, Penny Taylor, M. J. Mackie, Peter Donnan, Richard Boys, Anne Lennard, Robin J. Prescott

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

The aim of this study was to assess the feasibility of using objective data obtained at the time of diagnosis of Hodgkin's disease to predict those patients who were likely to die of progressive disease within four years. Nintey-two consecutive patients from one centre (Newcastle upon Tyne) were used to construct a numerical index based on disease stage (Ann Arbor), age, haemoglobin and absolute lymphocyte count. Weight was assigned according to a predictive value from univariate and multivariate analyses based on survival. The index produced was then validated on a separate patient set (455) from other centres within the Scotland and Newcastle Lymphoma Group (SNLG) on whom the same prospective information was available. The index produced provided a useful separation of those patients destined to die of disease. In 101 patients with index >0.5, 62 (61.4% were dead at four years, whereas with index <0.5, 61 (18% of 336 patients were dead at four years. The index includes Ann Arbor stage but possesses additional practical prognostic value which allows identification of patients with early stage destined to die of disease. Of 149 patients with Stage IA and IIA disease 15 patients had index >0.5, and 10 (60% have died, whereas the remaining patients had survival of 90% and 85% respectively. This numerical index has now been strengthened by an added factor for bulk disease > 10 cms and in the SNLG it has replaced Ann Arbor staging for selection of patients requiring aggressive therapy. A randomized study of chemotherapy versus chemotherapy plus autotransplant in first remission using high dose melphalan and VP16 is currently in progress.

Original languageEnglish
Pages (from-to)17-20
Number of pages4
JournalLeukemia and Lymphoma
Volume7
Issue numberS1
DOIs
Publication statusPublished - 1 Jan 1992

Fingerprint

Hodgkin Disease
Scotland
Lymphoma
Drug Therapy
Melphalan
Survival
Autografts
Lymphocyte Count
Patient Selection
Hemoglobins
Multivariate Analysis
Weights and Measures

Keywords

  • Clinical use
  • Diagnosis
  • Hodgkin's disease
  • Numerical prognostic index

Cite this

Proctor, Stephen J. ; Taylor, Penny ; Mackie, M. J. ; Donnan, Peter ; Boys, Richard ; Lennard, Anne ; Prescott, Robin J. / A numerical prognostic index for clinical use in identification of poor-risk patients with hodgkin's disease at diagnosis. In: Leukemia and Lymphoma. 1992 ; Vol. 7, No. S1. pp. 17-20.
@article{aabe01e5abfe4a2a83ac074b751d095b,
title = "A numerical prognostic index for clinical use in identification of poor-risk patients with hodgkin's disease at diagnosis",
abstract = "The aim of this study was to assess the feasibility of using objective data obtained at the time of diagnosis of Hodgkin's disease to predict those patients who were likely to die of progressive disease within four years. Nintey-two consecutive patients from one centre (Newcastle upon Tyne) were used to construct a numerical index based on disease stage (Ann Arbor), age, haemoglobin and absolute lymphocyte count. Weight was assigned according to a predictive value from univariate and multivariate analyses based on survival. The index produced was then validated on a separate patient set (455) from other centres within the Scotland and Newcastle Lymphoma Group (SNLG) on whom the same prospective information was available. The index produced provided a useful separation of those patients destined to die of disease. In 101 patients with index >0.5, 62 (61.4{\%} were dead at four years, whereas with index <0.5, 61 (18{\%} of 336 patients were dead at four years. The index includes Ann Arbor stage but possesses additional practical prognostic value which allows identification of patients with early stage destined to die of disease. Of 149 patients with Stage IA and IIA disease 15 patients had index >0.5, and 10 (60{\%} have died, whereas the remaining patients had survival of 90{\%} and 85{\%} respectively. This numerical index has now been strengthened by an added factor for bulk disease > 10 cms and in the SNLG it has replaced Ann Arbor staging for selection of patients requiring aggressive therapy. A randomized study of chemotherapy versus chemotherapy plus autotransplant in first remission using high dose melphalan and VP16 is currently in progress.",
keywords = "Clinical use, Diagnosis, Hodgkin's disease, Numerical prognostic index",
author = "Proctor, {Stephen J.} and Penny Taylor and Mackie, {M. J.} and Peter Donnan and Richard Boys and Anne Lennard and Prescott, {Robin J.}",
year = "1992",
month = "1",
day = "1",
doi = "10.3109/10428199209061558",
language = "English",
volume = "7",
pages = "17--20",
journal = "Leukemia & Lymphoma",
issn = "1042-8194",
publisher = "Taylor & Francis",
number = "S1",

}

A numerical prognostic index for clinical use in identification of poor-risk patients with hodgkin's disease at diagnosis. / Proctor, Stephen J.; Taylor, Penny; Mackie, M. J.; Donnan, Peter; Boys, Richard; Lennard, Anne; Prescott, Robin J.

In: Leukemia and Lymphoma, Vol. 7, No. S1, 01.01.1992, p. 17-20.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A numerical prognostic index for clinical use in identification of poor-risk patients with hodgkin's disease at diagnosis

AU - Proctor, Stephen J.

AU - Taylor, Penny

AU - Mackie, M. J.

AU - Donnan, Peter

AU - Boys, Richard

AU - Lennard, Anne

AU - Prescott, Robin J.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - The aim of this study was to assess the feasibility of using objective data obtained at the time of diagnosis of Hodgkin's disease to predict those patients who were likely to die of progressive disease within four years. Nintey-two consecutive patients from one centre (Newcastle upon Tyne) were used to construct a numerical index based on disease stage (Ann Arbor), age, haemoglobin and absolute lymphocyte count. Weight was assigned according to a predictive value from univariate and multivariate analyses based on survival. The index produced was then validated on a separate patient set (455) from other centres within the Scotland and Newcastle Lymphoma Group (SNLG) on whom the same prospective information was available. The index produced provided a useful separation of those patients destined to die of disease. In 101 patients with index >0.5, 62 (61.4% were dead at four years, whereas with index <0.5, 61 (18% of 336 patients were dead at four years. The index includes Ann Arbor stage but possesses additional practical prognostic value which allows identification of patients with early stage destined to die of disease. Of 149 patients with Stage IA and IIA disease 15 patients had index >0.5, and 10 (60% have died, whereas the remaining patients had survival of 90% and 85% respectively. This numerical index has now been strengthened by an added factor for bulk disease > 10 cms and in the SNLG it has replaced Ann Arbor staging for selection of patients requiring aggressive therapy. A randomized study of chemotherapy versus chemotherapy plus autotransplant in first remission using high dose melphalan and VP16 is currently in progress.

AB - The aim of this study was to assess the feasibility of using objective data obtained at the time of diagnosis of Hodgkin's disease to predict those patients who were likely to die of progressive disease within four years. Nintey-two consecutive patients from one centre (Newcastle upon Tyne) were used to construct a numerical index based on disease stage (Ann Arbor), age, haemoglobin and absolute lymphocyte count. Weight was assigned according to a predictive value from univariate and multivariate analyses based on survival. The index produced was then validated on a separate patient set (455) from other centres within the Scotland and Newcastle Lymphoma Group (SNLG) on whom the same prospective information was available. The index produced provided a useful separation of those patients destined to die of disease. In 101 patients with index >0.5, 62 (61.4% were dead at four years, whereas with index <0.5, 61 (18% of 336 patients were dead at four years. The index includes Ann Arbor stage but possesses additional practical prognostic value which allows identification of patients with early stage destined to die of disease. Of 149 patients with Stage IA and IIA disease 15 patients had index >0.5, and 10 (60% have died, whereas the remaining patients had survival of 90% and 85% respectively. This numerical index has now been strengthened by an added factor for bulk disease > 10 cms and in the SNLG it has replaced Ann Arbor staging for selection of patients requiring aggressive therapy. A randomized study of chemotherapy versus chemotherapy plus autotransplant in first remission using high dose melphalan and VP16 is currently in progress.

KW - Clinical use

KW - Diagnosis

KW - Hodgkin's disease

KW - Numerical prognostic index

UR - http://www.scopus.com/inward/record.url?scp=0026770006&partnerID=8YFLogxK

U2 - 10.3109/10428199209061558

DO - 10.3109/10428199209061558

M3 - Article

C2 - 1493453

AN - SCOPUS:0026770006

VL - 7

SP - 17

EP - 20

JO - Leukemia & Lymphoma

JF - Leukemia & Lymphoma

SN - 1042-8194

IS - S1

ER -